High concentration formulation

A topical pharmaceutical formulation comprising cortexolone-17α-propionate at a concentration of about 5 weight percent to about 15 weight percent, and a pharmaceutically acceptable amount of one or more pharmaceutically acceptable solvents, wherein the cortexolone-17α-propionate is fully solubilized in the formulation, wherein the formulation contains less than about 5 percent water;

• and wherein topically administering the effective amount of the formulation provides at least one of the following effects:
• (a) a mean steady-state Cmax of cortexolone-17α-propionate of about 2 ng/ml to about 6 ng/ml after topical application of a single dose;
• or (b) a mean steady-state Tmax of cortexolone-17α-propionate from about 2 to about 7 hours after topical application of a single dose;
• or
• (c) a mean steady-state AUC from about 20 (ng*h)/ml to about 55 (ng*h)/ml after topical application of a single dose of cortexolone-17α-propionate.